Review and cohort analysis reveals higher response rates after stem cell transplantation in immunoglobulin light-chain amyloidosis, indicating improved prognostic markers for overall survival.
PURPOSE OF REVIEW: High-dose chemotherapy increasingly is being used for the management of patients with immunoglobulin light-chain amyloidosis. We describe nearly 300 patients who had treatment combining high-dose chemotherapy and stem cell transplantation at Mayo Clinic and review the recent literature. RECENT FINDINGS: We review outcomes, engraftment data, and predictors of early mortality. The survival benefit of transplantation, however, has not been verified in a phase III clinical trial. SUMMARY: Partial response rates and complete response rates are prognosticators of survival for patients with amyloidosis. These rates are much higher for patients who receive high-dose therapy and transplantation.
No takes yet. Share an insight, caveat, or question.
Gertz et al. (2007) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: